For example, Hanash et al.'s group reported that IL-22 functions as a critical regulator of tissue sensitivity to GVHD via activation of IL-22R1 expressed on intestinal stem cells, whereas our group determined that treatment with IL-22Ab increased the number of Foxp3+ T cells regulating IL-22R1 expressed on CD11b+ cells. This evidence concerns the gene FOXP3 and graft versus host disease.